Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAssociation of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial

In this phase 3 nonrandomized controlled trial of 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) had a median OS of 19.3 months from randomization (22.4 months from surgery), while contemporaneous, matched external control patients receiving SOC had a median OS of 16.5 months from randomization; for patients with recurrent glioblastoma (rGBM), the median OS was 13.2 months from relapse in the DCVax-L group vs. 7.8 months in the external control cohort. Both in nGBM and rGBM, significant increases in the long-term tails of the survival curves were seen.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form